Clevegen
Clevegen is a new cancer immunotherapy drug under development in Finland by Faron Pharmaceuticals. The drug is an anti-Clever-1 antibody which can convert immune suppressive type-2 tumour-associated macrophages (TAMs) to immune active type-1 microphages and has the potential for wide use in oncology. It is currently (2019) undergoing trials (codename MATINS) as an innovative treatment for metastatic or inoperable solid tumours such as cutaneous melanoma and hepatobiliary/hepatocellular, pancreatic, ovarian and colorectal cancers, all of which host a significant number of Clever-1-positive TAMs and represent some 2 million cases annually worldwide.
product
Link from a Wikipage to another Wikipage
primaryTopic
Clevegen
Clevegen is a new cancer immunotherapy drug under development in Finland by Faron Pharmaceuticals. The drug is an anti-Clever-1 antibody which can convert immune suppressive type-2 tumour-associated macrophages (TAMs) to immune active type-1 microphages and has the potential for wide use in oncology. It is currently (2019) undergoing trials (codename MATINS) as an innovative treatment for metastatic or inoperable solid tumours such as cutaneous melanoma and hepatobiliary/hepatocellular, pancreatic, ovarian and colorectal cancers, all of which host a significant number of Clever-1-positive TAMs and represent some 2 million cases annually worldwide.
has abstract
Clevegen is a new cancer immun ...... eloid cell staining technique.
@en
Wikipage page ID
62,511,304
page length (characters) of wiki page
Wikipage revision ID
929,750,913
Link from a Wikipage to another Wikipage
wikiPageUsesTemplate
comment
Clevegen is a new cancer immun ...... lion cases annually worldwide.
@en
label
Clevegen
@en